submit to the journals

ASH Highlights

flipper_slider

Editor's Choice

At ASH 2018 editorial board member, Dr Mohamad Mohty, discusses Epstein-Barr virus associated post-transplant lymphoproliferative disorder (EBVPTLD) and developments in its treatment. EBVPTLD is a serious,...

ASH Highlights Videos

Professor Maria Domenica Cappellini joined touchONCOLOGY at ASH 2018 to discuss haematologists' approach to Gaucher disease, focusing on the diagnosis and follow-up of this rare genetic condition. Professor Cappellini outlines the current issue of slow diagnosis times, and emphasises the importance...
In this interview, filmed at ASH 2018, Dr Robin Foà talks to touchONCOLOGY about recent developments in the treatment of haematological malignancies, namely the identification of new genetic abnormalities, the increase in chemotherapy-free treatments, and the use of molecular technologies to...
In this interview, filmed at ASH 2018, Dr Constantine Mitsiades talks to touchONCOLOGY about the current and future treatment landscape of multiple myeloma. One of the most significant recent developments in the treatment of multiple myeloma, has been monoclonal antibodies (mAbs), particularly...
At ASH 2018 editorial board member, Dr Mohamad Mohty, discusses Epstein-Barr virus associated post-transplant lymphoproliferative disorder (EBVPTLD) and developments in its treatment. EBVPTLD is a serious, life-threatening condition which can occur as a result allogeneic stem cell transplantation...
Dr Wadie Bahou answers our questions about the role of platelets in tumor biology and metastasis and the significance and usefulness of platelet-related biomarkers in the detection and monitoring of hematologic and oncologic diseases. Questions: 1. What is the role of platelets in tumor biology...
In this interview filmed at ASH 2018, Dr Austin Kulasekararaj discusses the phase III non-inferiority study investigating ravulizumab (ALXN1210) versus eculizumab in adult patients with paroxysmal nocturnal hemoglobinuria in patients currently treated with eculizumab. He then goes on to discuss how...
We spoke to Professor Morie Getz at ASH 2018 about the current unmet needs in treatment of hereditary TTR amyloidosis, antisense technology, inotersen and the NEURO-TTR study. Questions: 1. What is hereditary TTR amyloidosis and what are the unmet needs in its treatment? (0:10) 2. Could you...
Professor Nicolaus Kröger spoke to us at ASH 2018 about the major unmet needs in the treatment of myelodysplastic syndrome in elderly patients, and his phase III study comparing 5-azacytidine induction followed by allogeneic stem cell transplantation versus continuous 5-azacytidine according to...
Mohamad Mohty talks about the emergence of novel therapies and treatments strategies and the place of stem cell transplantation in multiple myeloma.
Rodrigo T Calado discusses the role of telomere shortening in bone marrow failure at ASH 2017.
Joseph M Connors discusses the rationale, design and results of the ECHELON-1 study of combined brentuximab vedotin and chemotherapy.
John D Grainger talks about his management approach to pediatric ITP and the goals of the UK paediatric ITP registry at ASH 2017.
Wojciech Jurczak discusses the two phase III trials of rituximab biosimilars published earlier this year and how the European approval of rituximab biosimilars has impacted on follicular lymphoma treatment.
Eliezer Rachmilewitz discusses the current status of gene therapy and editing for hemoglobinopathies.
James B Bussel talks about the unmet needs in the treatment of adult and pediatric ITP, and the recent finding of fostamatinib in adult persistent/chronic ITP.